Welcome to Novatek Pharmaceuticals
Novatek Pharmaceuticals is a company with a renowned team leading clinical investigations focused on development of immunomodulatory drugs related to cancers and infectious diseases. Empowering naturally derived immunotherapy that is effective across various cancer types, with the goal of effectively boosting the immune system and T cell population in patients while reducing the adverse effects of disease or cytotoxic therapies.
We primarily work with Nigella Sativa (Black seeds) a natural derivative incorporated within our proprietary drug NP-101. Clinical trials conducted in 2021 demonstrated that NP-101 has applications for immunotherapy and cancer treatment showcasing significant effect on T cells. The Novatek team has 100+ years of clinical research and pharmaceutical development experience, resulting in 400+ peer reviewed publications and a strong pharmaceutical pipeline.
Dr. Ahmed Kaseb founded Novatek Pharmaceuticals to conduct clinical research with a proprietary compound, NP-101, to address the need for immunomodulatory drugs . NP-101 is naturally derived from the seeds of the Nigella Sativa plant, commonly referred to as “black seeds”.
Novatek Pharmaceuticals Inc., was recently formed based on years of experience with n-sativa in oncology patients combined with recent publications. Raising Series A to finance clinical trials in various cancers and to further develop the pipeline.
Novatek Pharmaceuticals main target is the concentrated form of the black seed oil. Black seed oil is a natural product with therapeutic potential in management of cancers and infectious diseases. NP-101 is the proprietary drug, naturally derived from this compound
We provide scientific guidance to the Consortium and advice on the strategic direction of our Project scientific guidance
LEARN MORE
N-Sativa, a component of NP-101, may block the SARS-CoV-2 entry via ACE2 in pneumocytes. N. sativa oil and n-sativa produce antinociceptive effects through indirect activation of supraspinal μ1- and κ-opioid receptor subtypes.
LEARN MORE
There is a pending story in collaboration with case CWRU School of Medicine to study the effect of NP-101 and cancer patients. Stay current with the latest news and events from Novatek Pharmaceuticals.
COMING SOON
Novatek Pharmaceuticals Initiates a Randomized, Double-Blinded, Placebo-Controlled Phase 2 Study Of Its Oral Drug, NP-101, Against Novel Coronavirus 2019 (COVID-19) In The Outpatient Setting
LEARN MORE
In order to best meet our patients needs, Pyramids Pharmacy delivers Ground or Overnight, five days a week. You can be confident the medications will be delivered when needed.
LEARN MORE
Novatek Pharmaceuticals Initiates a Randomized, Double-Blinded, Placebo-Controlled Phase 2 Study Of Its Oral Drug, TQ Formula, Against Novel Coronavirus 2019 (COVID-19) In The Outpatient Setting
LEARN MORE
Thymoquinone may block the SARS-CoV-2 entry via ACE2 in pneumocytes. N. sativa oil and thymoquinone produce antinociceptive effects through indirect activation of supraspinal μ1- and κ-opioid receptor subtypes.
LEARN MORE
We provide scientific guidance to the Consortium and advice on the strategic direction of our Project scientific guidance
LEARN MORE
Novatek Pharmaceuticals main target is Black seed oil. Black seed oil is a natural product with therapeutic potential in management of SARS-CoV-2 due to its anti-viral activity.
LEARN MORE
Novatek Pharmaceuticals Inc., was recently formed based on years of experience with thymoquinone in oncology patients combined with recent publications.
Founders Mohamed, Osama and Karim, created Novatek Pharmaceuticals to develop and commercialize an innovative therapeutic approach to treat COVID-19. In other words, our product was driven by wanting to provide effective results to offer great health benefits with quality that lives up to the highest standards.
LEARN MORE
Novatek Pharmaceuticals Initiates a Randomized, Double-Blinded, Placebo-Controlled Phase 2 Study Of Its Oral Drug, TQ Formula, Against Novel Coronavirus 2019 (COVID-19) In The Outpatient Setting
LEARN MORE
What we do
Novatek Pharmaceuticals main target is Black seed oil. Black seed oil is a natural product with therapeutic potential in management of SARS-CoV-2 due to its anti-viral activity.
LEARN MORE
Novatek Pharmaceuticals was founded by Dr. Ahmed Kaseb, MD.
Dr. Kaseb is a Professor at the University of Texas, MD Anderson Cancer Center.
LEARN MORE
Who we are
Novatek Pharmaceuticals Inc., was recently formed based on years of experience with thymoquinone in oncology patients combined with recent publications.
Connect with us
In order to best meet our patients needs, Pyramids Pharmacy delivers Ground or Overnight, five days a week. You can be confident the medications will be delivered when needed.
LEARN MORE
Thymoquinone may block the SARS-CoV-2 entry via ACE2 in pneumocytes. N. sativa oil and thymoquinone produce antinociceptive effects through indirect activation of supraspinal μ1- and κ-opioid receptor subtypes.
LEARN MORE
We provide scientific guidance to the Consortium and advice on the strategic direction of our Project scientific guidance
LEARN MORE
About Our Products
Black seed oil is a natural product with therapeutic potential in management of Cancer, SARS-CoV-2 and various diseases due to its anti-viral activity. Derived from Nigella Sativa plant, it has been extensively studied and shown to possess a wide spectrum of activities which include antibacterial, antifungal and antiviral effects among many others. These “black seeds” are utilized in NP-101 our naturally derived proprietary drug.
PRESS RELEASE:
Novatek Pharmaceuticals Initiates A Randomized, Double-Blinded, Placebo-Controlled Phase 2 Study Of Its Oral Drug, NP-101, Against Novel Coronavirus 2019 (COVID-19) In The Outpatient Setting
Contact Us
Thank you for your interest in Novatek Pharmaceuticals. we look into all the messages send to us and we reply back to them in a timely manner